Search PubMed⌕ Search

Biomedical subjects

J Pigneux

Publications and source records attributed to J Pigneux.

At least 55 records · Page 3Linked to original sources

[Malignant astrocytoma and glioblastoma. Therapeutic results].

Statistical analysis of therapeutic results in malignant gliomas is impeded by the discrepancies between the various classifications. We have distinguished glioblastomas from malignant astrocytomas. The latter are defined as malignant gliomas other than glioblastomas with CT scan enhancement after IV contrast. The discrimination between these two types of tumor is justified by the very different actuarial survival curves. Total survival was not prolonged by chemotherapy in randomized studies. Systematic sequential treatment of glioblastomas with VM26-CCNU is questionable.

Astrocytoma↗

[The diagnosis and therapeutic malignant gliomas management (author's transl)].

3 principles lead, in our opinion, the malignant gliomas management: to place surgery in first position, to take prognostic factors into account, to require a convincing histological evidence before deciding on radiotherapy and chemotherapy. 111 cases are studied: in 8% of cases stereotax biopsies allow correction of CT scan diagnosis. The survival curves could be carefully interpreted according to patient and tumor features.

Biopsy↗

[Squamous-cell carcinoma of the uvula and the soft palate. Analysis of a series of 71 cases seen at the Fondation Bergonié from 1971 to 1978 (author's transl)].

From January 1971 through december 1978, 71 patients with a squamous-cell carcinoma of the uvula and the soft palate have been seen at the Fondation Bergonié : 56 have been treated and followed. The primary tumor is often controlled by external radiation-therapy and/or interstitial therapy among the 12 failure observed, 5 were salvaged by a surgical procedure. The systematic irradiation of cervical lymph nodes areas allowed 94% of control, above the clavicles. However these good results in the loco-regional control are altered by a high rate of second primary and intercurrent death.

Adult↗

[Tomodensitometry in stereotaxic conditions (possibilities and limitations in the diagnosis and treatment of brain lesions)].

The stereotaxic approach of cerebral lesions for diagnostic (biopsies) and/or therapeutic purposes (interstitial radiotherapy) has been well documented. These techniques depend on an exact spatial definition of the tumoral volume, which is often difficult to obtain through conventional neuroradiology, stereoencephalography, rheography... The use of tomodensitometry in this context is obviously of upmost interest if, and only if, the scan itself is obtained in stereotaxic conditions. The authors present a stereotaxic system with which all the diagnostic data, including CT scan itself, are recorded and matched within the same stereotaxic space. This method achieves an exact mapping of lesions within the actual stereotaxic brain space. Hence any further stereotaxic gesture can be calculated and controlled with a suitable accuracy. The interest of these procedures in the management of brain lesions is demonstrated through an experience of 52 supra tentorial tumors. 13 cases of lesions under 20 mm in diameter are especially discussed.

Brain Abscess↗

[Radiotherapy of stage T1-T2 M0 prostatic adenocarcinoma. Analysis of the carcinologic results of a multicenter study of 610 patients. Groupe Radiothérapie de la Commission de Coopération Médicale Intercentres (CCMI)].

PURPOSE: Retrospective analysis of the results of radiotherapy in localized prostatic adenocarcinoma. Complications were excluded. PATIENTS AND METHODS: Six-hundred-and-ten T1-T2 adenocarcinomas of the prostate were treated with continuous courses of external beam radiation therapy in 19 participating Institutes between January 1983 and January 1988. The mean follow-up was 10.4 years; the mean age of patients at the beginning of radiotherapy was 68.5 years. RESULTS: A 10-year, local control had been achieved in 86% of T1-T2 (81.4% for T2). The 5- and 10-year metastatic relapse rates were 25.3% and 30% (29% and 38.1% for T2), respectively. At 10 years, 62.4% of T1-T2 were recurrence-free; overall survival rate was 45.8% and cause-specific survival rate was 70.5%; 29.9% of T1-T2 patients were alive and disease-free. T category (TNM), pathologic grade, pelvic lymph node status, local tumor control, and obstructive ureteral symptoms were correlated with survival. The influence of pelvic nodes radiation, dose, overall treatment time, previous endocrine treatment, and transuretral resection was not significant for disease-free survival (alive and disease-free) and other endpoints. CONCLUSION: There was no difference between the French series (1975-1982 and 1983-1988). The results of the literature are comparable to ours. As far as prognostic factors are concerned, this report provides evidence that the explainable variables which influence survival depend on the tumor and patient status.

Adenocarcinoma↗